A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-15

Study Completion Date

2021-02-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase 1b/2 study will examine the effects of the study drugs, avelumab, binimetinib and talazoparib when given in a 2 (doublet) or 3 (triplet) drug combination, in patients with locally advanced or metastatic RAS-mutant solid tumors. The Phase 1b part of the study will assess if the different study drugs can be given together safely and which doses to use for further research. Phase 2 will test if the study treatments have an effect on tumor size and growth, and gather more information about potential side effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

NCT04983407

Pancreatic Adenocarcinoma

TERMINATED PHASE1/PHASE2

Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer

NCT00470535

Pancreatic Cancer

TERMINATED PHASE2

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

NCT01010945

Advanced Pancreatic Cancer

COMPLETED PHASE1

Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer

NCT00307723

Pancreatic Cancer Pancreatic Ductal Adenocarcinoma

TERMINATED PHASE1/PHASE2

Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer

NCT00366457

Pancreatic Cancer Adenocarcinoma of the Pancreas

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1b/2, open label, multi-center, safety, clinical activity, pharmacokinetic (PK), and pharmacodynamics (PD) study of combinations of avelumab, binimetinib and talazoparib in adult patients with metastatic pancreatic ductal adenocarcinoma and other locally advanced or metastatic KRAS- or NRAS-mutant solid tumors.

The Phase 1b part of this study will initially assess doublet drug combinations to determine a recommended dose for further investigation. Following this, the recommended dose for the combination of avelumab, binimetinib and talazoparib (triplet) will be determined. The recommended doses for the doublet and triplet combinations will be used in the Phase 2 part of the study, which will assess the safety and preliminary anti-tumor activity of the study treatments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

Oral treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Avelumab

IV treatment

Intervention Type DRUG

Binimetinib

Oral treatment

Intervention Type DRUG

Talazoparib

Oral treatment

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MSB0010718C MEK162 ARRY-438162 MDV3800, BMN 673

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent as follows:

1. Metastatic pancreatic ductal adenocarcinoma; or
2. Phase 2 only: Stage IIIb/IV NSCLC or other advanced solid tumors with documented positive KRAS or NRAS mutation as determined using a validated test performed in a CAP/CLIA-certified laboratory (or other comparable local or regional certification).
* Have had disease progression during or following at least 1 and not more than 2 prior lines of treatment for advanced or metastatic disease.
* Patients with NSCLC must have previously received treatment with an anti-PD-1 or anti-PD-L1 agent for advanced disease.
* Measurable disease as per RECIST v1.1 criteria.
* Provision of a baseline tumor sample.
* Age ≥18 years (Japanese patients must be ≥20 years old)
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
* Adequate bone marrow, renal and liver functions.
* Adequate cardiac function.
* Informed consent provided.

Exclusion Criteria

* Prior treatment with avelumab, a PARP inhibitor or MEK inhibitor.
* Prior systemic anti-cancer therapy within 2 weeks prior to study enrollment.
* Persisting toxicity related to prior therapy.
* Current use of immunosuppressive medication.
* Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, uveitis or iritis.
* Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
* Diagnosis of myelodysplastic syndrome (MDS).
* Known symptomatic brain metastases requiring steroids.
* Known history of testing positive for HIV or hepatitis.
* Clinically significant (ie, active) cardiovascular disease.
* History of thromboembolic or cerebrovascular events.
* Current or anticipated use of a P-gp inhibitor, inducer, or inhibitor of breast cancer resistance protein (BCRP)
* Uncontrolled hypertension.
* Concurrent neuromuscular disorder that is associated with the potential of elevated creatinine kinase.
* Known history of Gilbert's syndrome.
* History or current evidence of retinal degenerative disease, retinal vein occlusion (RVO) or current risk factors for RVO.
* Other acute or chronic medical or psychiatric condition.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No